Log in

NYSE:IQVIqvia Stock Price, Forecast & News

$159.64
-0.90 (-0.56 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$158.97
Now: $159.64
$160.93
50-Day Range
$135.99
MA: $149.78
$164.29
52-Week Range
$81.79
Now: $159.64
$169.14
Volume794,225 shs
Average Volume1.11 million shs
Market Capitalization$30.53 billion
P/E Ratio234.77
Dividend YieldN/A
Beta1.33
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
Iqvia logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.09 billion
Cash Flow$12.31 per share
Book Value$32.28 per share

Profitability

Net Income$191 million

Miscellaneous

Employees67,000
Market Cap$30.53 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$159.64
-0.90 (-0.56 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19 (Coronavirus)?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have increased by 27.3% and is now trading at $159.64.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia
.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia
.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) announced its earnings results on Wednesday, July, 22nd. The medical research company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.06 by $0.12. The medical research company had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same quarter last year, the business earned $1.53 EPS.
View Iqvia's earnings history
.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

What price target have analysts set for IQV?

17 Wall Street analysts have issued 12-month target prices for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they anticipate Iqvia's stock price to reach $165.00 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Iqvia
.

Has Iqvia been receiving favorable news coverage?

News stories about IQV stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Iqvia
.

Are investors shorting Iqvia?

Iqvia saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 2,490,000 shares, a decrease of 15.3% from the July 15th total of 2,940,000 shares. Based on an average trading volume of 1,230,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.3% of the company's stock are sold short.
View Iqvia's Short Interest
.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), Endologix (ELGX), Alibaba Group (BABA), Micron Technology (MU), Paypal (PYPL), Accenture (ACN) and salesforce.com (CRM).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by many different retail and institutional investors. Top institutional shareholders include Jackson Square Partners LLC (2.05%), Bessemer Group Inc. (0.92%), Sumitomo Mitsui Trust Holdings Inc. (0.67%), Victory Capital Management Inc. (0.45%), Swiss National Bank (0.40%) and Russell Investments Group Ltd. (0.35%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for Iqvia
.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Strs Ohio, Jennison Associates LLC, Sumitomo Mitsui Trust Holdings Inc., BI Asset Management Fondsmaeglerselskab A S, Banco Santander S.A., Victory Capital Management Inc., and State of Michigan Retirement System. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia
.

Which institutional investors are buying Iqvia stock?

IQV stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Veracity Capital LLC, Swiss National Bank, First Trust Advisors LP, Raymond James & Associates, Raymond James Financial Services Advisors Inc., Envestnet Asset Management Inc., and Dupont Capital Management Corp.
View insider buying and selling activity for Iqvia
.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $159.64.

How big of a company is Iqvia?

Iqvia has a market capitalization of $30.53 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

What is Iqvia's official website?

The official website for Iqvia is www.iqvia.com.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.